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ABSTRACT
With the high incidence of Lyme disease in the endemic areas of North America, it is
important to appropriately diagnosis and treat this condition to prevent post treatment Lyme
disease syndrome (PTLDS). Background information regarding Lyme disease is given. The
purpose of this paper is to discuss the treatment options available for those patients that fit the
case definition of PTLDS. A literature review was conducted using several different electronic
databases finding peer reviewed research articles pertaining to the treatment options available
for PTLDS. Extended antibiotic use is shown to be not beneficial in most cases. Alternative
treatment options listed on the internet are shown to be not evidence based. Therefore,
symptomatic treatment options seem to be the best positive outcome-based option available
for providers to use. These options are discussed in detail throughout this paper. Though much
more research is needed regarding the topic, this paper will give providers the information
currently available that they will need to know when treating patients with PTLDS. Hopefully
this will provide the patients with PTLDS the best outcome possible for improving their quality
of life post Lyme disease.
Keywords: Lyme disease, PTLDS, chronic Lyme disease, chronic fatigue syndrome, and
treatment outcomes

TREATMENT OPTIONS FOR POST TREATMENT LYME DISEASE SYNDROME

5

INTRODUCTION
Lyme disease is the most common vector borne illness in the USA, with over 300,000
new cases being reported every year (Rebman et al., 2017). Illness is caused by Borrelia
burgdorferi (Bb) passed to humans by the Ixodes genus of the black legged deer tick. Lyme
disease is endemic in the United States with most disease being acquired in the Northeast and
upper Midwest states but can also be found along the Pacific coast. In these endemic areas it is
important for family practice providers to educate their patients regarding prevention. This
would include avoidance of exposure to ticks by using insect repellent and appropriate
coverage of clothing. It would also include daily inspection of themselves, children, and pets
when in areas of high prevalence such as the woods, brush, or tall grass. With a weak
recommendation by DynaMed Plus, Lyme disease (2018), prophylactic antibiotic treatment of a
single 200 mg oral dose of doxycycline can be given within 72 hours of tick removal if the Ixodes
species tick is identified and was adherent for at least 36 hours.
According to DynaMed Plus, Lyme Disease (2018), when infected with Lyme disease,
different clinical presentations exist including erythema migrans (EM), a localized skin reaction,
which is the most common manifestation of Lyme disease and is alone diagnostic where no
further testing is needed. Early disseminated disease may also present as carditis, typically
atrioventricular conduction disturbances, or neuritis, such as cranial nerve palsy or meningitis.
Late Lyme disease may present as arthritis involving a large joint or chronic neurologic disease
such as peripheral neuropathy or encephalopathy.
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In patients with symptoms other than EM, 2-tiered serologic testing can be performed
by the laboratory, but this testing is not without complications of its own. Serologic testing has
evolved over the years, improving sensitivity of the enzyme-linked immunosorbent assays
(ELISA) as the way to screen for Lyme disease but it has been found that as many as 50% of
patients will test seronegative in the early course of the illness (Halperin, 2015). Western blot
should not be ordered on patients who are seronegative. Western blot provides specificity if
the screening test comes back positive but can be difficult to interpret. Patients with disease of
more than 1-month or 2-month duration should be IgG seropositive, so IgG blots provide the
most reliable information (Halperin, 2015). According to DynaMed Plus, Lyme disease (2018),
do not retest patients who report persistent symptoms to determine if antibody titers have
increased or decreased because seroreactivity does not correlate with ongoing symptoms.
Increased titers often persist in most patients for at least months after treatment of early
infection, and for years after treatment of late infection. Rebman, Crowder, Kirkpatrick, and
Aucott (2015) conducted a prospective cohort study which highlighted and supported the
difficulty in relying on serologic testing to confirm prior exposure not only in early disease but
also in identification of later cases of antibiotic-refractory symptoms of post-treatment Lyme
disease syndrome (PTLDS).
Guidelines have been set up for the initial treatment regimen of Lyme disease with
strong recommendation by DynaMed Plus, Lyme disease (2018). Doxycycline is the antibiotic of
choice for EM, Lyme arthritis, and cranial nerve palsy. Hospitalization and IV ceftriaxone are
often required for Lyme carditis and neurologic Lyme disease other than cranial nerve palsy.
Dose and duration are specified for the different types of symptoms. Providers need to make
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sure to differentiate the presentations of Lyme disease as early as possible and treat
appropriately. Misdiagnosis or inappropriate treatment may lead to an increase in likelihood of
developing persistent symptoms following treatment.
Statement of the Problem
Primary care providers still struggle to appropriately diagnosis and treat Lyme disease.
Even though treatment guidelines have been established for prophylaxis and initial treatment
of Lyme disease, controversy continues within the medical field questioning if long term
symptoms such as fatigue, pain, joint and muscle aches, memory and concentration deficits
after Lyme treatment do truly exist. Feng et al. (2017) have estimated that approximately 1020% of patients continue suffering from chronic symptoms described as PTLDS following the
standard antibiotic treatment of 2-4 weeks for early or late Lyme disease. The question
remains that even if these symptoms are a direct or indirect consequence of Lyme disease, how
can providers appropriately treat these patients.
Statement of the Research Question
In patients who were treated appropriately for Lyme disease but develop PTLDS, does
extended course antibiotic therapy versus symptomatic treatment versus alternative
treatments help relieve PTLDS symptoms most effectively?
LITERATURE REVIEW
A comprehensive search was performed using several electronic databases including
DynaMed Plus, PubMed, Clinical Key, and CINAHL. Specific key words used in the search for this
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topic included Lyme disease, PTLDS, chronic Lyme disease, chronic fatigue syndrome, and
treatment outcomes. A review of the literature yielded several high-quality randomized control
trials, prospective cohort studies, and case control studies published primarily within the past 5
years. Two articles going back to 2001 and 2007 were included because it is important to
establish how long the struggle of treating Lyme Disease and PTLDS has existed. The articles
also show how there have not been many advances made in diagnosis or treatment throughout
the years. Studies were limited to those which provided good background information and high
levels of evidence regarding treatment options that have been studied thus far and did not
include conflict of interest.
Evidence of PTLDS
The Infectious Diseases Society of America proposed a case definition for PTLDS in 2006
as:
‒ An adult or child with a documented episode of early or late Lyme disease
fulfilling the case definition of the Centers for Disease Control and Prevention
‒ Treatment with a generally accepted treatment regimen, with resolution or
stabilization of the objective manifestation(s) of Lyme disease
‒ Onset of any of the following subjective symptoms within 6 months of the
diagnosis of Lyme disease and persistence of continuous or relapsing symptoms
for at least a 6 month period after completion of antibiotic therapy:
• Fatigue
• Widespread musculoskeletal pain
• Complaints of cognitive difficulties
• Subjective symptoms are of such severity that, when present, they result in
substantial reduction in previous levels of occupational, educational, social, or
personal activities. (Nemeth et al., 2016, Table 1)
A recent study was published by Rebman et al. (2017) that characterized a case series of
patients with well-documented PTLDS comparing them to a sample of healthy control subjects.
This case series study included 61 participants which were physician-referred or self-referred
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and met the case definition of PTLDS. The normal control group consisted of 26 healthy control
participants that did not have a clinical history of Lyme disease or current antibodies to Bb. All
participants in the study were evaluated by physical exam, clinical laboratory testing,
standardized questionnaires, and a 36-item current symptom list. Comparison was made
between the control group and all participants with PTLDS. Rebman et al. (2017) found that
59% of the participants with PTLDS were misdiagnosed initially or had delayed initial diagnosis
of Lyme disease proving the importance of proper and timely diagnosis and treatment. A case
series study provides low evidence about therapeutic effectiveness, but this study was a first
for comparing patients with rigorously defined PTLDS to the non-Lyme infected control group.
All participants, including the normal controls, were taken from an appropriate endemic area
for Lyme disease. The studies confounding effect brings to attention that there is no definitive
biomarker for Bb infection or PTLDS. This causes uncertainty that symptoms are attributable to
PTLDS and not other co-morbidities. The authors did try to address this by following the same
exclusionary criteria for all participants. The physical exams and laboratory testing provided by
Rebman et al. (2017) showed few abnormalities with the most notable exception being 32.2%
diminished vibratory sensation on physical exam among the participants with PTLDS.
Therefore, standardized questionnaires were utilized to measure symptoms. The results
showed significantly greater fatigue, pain, sleep disturbance, depression and lower quality of
life occurred in the patients with PTLDS (p<0.001) (Rebman et al., 2017). This study hopes to
provide a pattern of symptoms that can be used as a tool for the diagnosis for PTLDS. It also
hopes to provide a well-validated symptom survey that can be used to monitor treatment since
laboratory testing has been shown to be unreliable.
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Identifying the cause of PTLDS may be beneficial in establishing treatment guidelines.
One hypothesis is that the existence of PTLDS occurs because the Bb spirochetes or spherules
from the spirochetes remain in this subset of patients even after treatment. Middelveen et al.
(2018) performed a case-control study where 12 subjects were randomly chosen from the
North American patient population. All were either clinically diagnosed with Lyme disease or
tested positive for serological testing prior to the study. All patients had been treated with
antibiotics and symptomatic patients who remained on antibiotics were also included in the
study. Ten healthy subjects who tested negative for serologic testing were used as controls. All
12 positive case studies were described in detail for symptoms and sample types were taken for
culture from all participants. The study confirmed the presence of live Borrelia spirochetes with
positive cultures in these patients who were treated with antibiotics but remained
symptomatic. In contrast, all the control subjects were negative for Borrelia spirochetes.
These positive results are shown in Table 1.
Middelveen et al. (2018) clearly defines and describes the cases well. A problem with
this study group was that it defined a very small percent of the population and the study admits
to some of the subjects not being from an endemic area. The control subjects were randomly
selected, and all appropriately tested. The control group was selected from the same
population as the study group. Study measures were not identical as different culture
specimens were sampled depending on the subjects. It was not explained how the type of
culture specimen collected per patient was determined. The specimen types varied between
whole callus, blood culture, vaginal, or seminal cultures. The study measures were objective.
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These results mirror studies performed on non-human primates previously. Clinical studies on
a larger scale with human participants are needed to confirm these findings.
Table 1. Summary of Microscopy Results from Patient Culture Samples
Case#

Sample Type

Darkfield

Dieterle

Bb Immunostain

Case1

whole callus
blood culture

NIA

spirochetes

positive, spirochetes

spi rochetes

N/A

NIA

Case2

blood cu lture
vaginal culture

spherules
spirochetes

spherules
spirochetes

positive, spherules
positive, spirochetes, biofilm

Case3

blood culture
seminal culture

spirochetes/spherules
spi rochetes

spirochetes/ spherules
spirochetes

positive spirochetes/spherules
positive, spirochetes

Case4

blood cu lture
vaginal culture

spirochetes/spherules
spirochetes

spirochetes/ spherules
spirochetes

positive spirochetes/spherules
positive, spirochetes

Cases

blood culture
vaginal culture

spherules
spirochetes

spherules
spirochetes

positive, spherules
positive, spirochetes

Case6

blood culture
seminal culture

spherules
spirochetes

spherules
spirochetes

positive, spherules
positive, spirochetes

Case7

vaginal culture

spirochetes

spirochetes

positive, spirochetes

Case8

seminal culture

spirochetes

spirochetes

positive, spirochetes

Case9

vaginal culture

spirochetes

spirochetes

positive, spirochetes

Case 10

seminal culture

spirochetes

spirochetes

positive, spirochetes

Case l 1

vaginal culture

spirochetes

spirochetes

positive, spirochetes

Case 12

blood cu lture
skin culture

spherules
spirochetes

spherules
spirochetes

positive, spherules
positive, spirochetes

NI A, not available.

Note. Adapted from “Persistent Borrelia infection in patients with ongoing symptoms of Lyme
disease”, by Middelveen, M., Sapi, E., Burke, J., Filush, K. R., Franco, A., Fesler, M. C., & Stricker,
R. B., 2018, Healthcare, 6(2), pii:E33. Copyright 2018 by the authors.
Treatment of PTLDS with Extended Use of Antibiotics
Studies going back to 2001 prove that extended use of intravenous and oral antibiotics
for greater than 90 days does not improve symptoms more than placebo groups. Klempner et
al. (2001) conducted a randomized control trial to determine if long term antibiotic use was
beneficial in improving health-related quality of life in patients previously diagnosed and
treated for Lyme disease. The study included 78 patients who were still seropositive for IgG
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antibodies to Borrelia burgdorferi and the control group included 51 patients who were
seronegative. Patients were randomly selected on a 1:1 ratio to receive IV ceftriaxone for 30
days and then oral doxycycline for 60 days or placebo IV dextrose solution and placebo oral
capsules for same amount of time. Using the Medical Outcomes Study 36-Item Short-Form
General Health Survey (SF-36) it was determined that considerable impairment of healthrelated quality of life was seen in both groups. Table 2 shows that the criteria evaluated
produced very similar confidence intervals of 95% across both groups. This shows that there
was no statistical difference between the patients receiving extended antibiotics and those who
did not.
Table 2. Clinical Responses at 180 Days

TABLE 2 , CLINICAL RllSl'ONSF.S AT 180 DAYS.*

Sf"36 OUTCOME
S EROPOSrTrvE PATIENTS

CATEGORY

AhTIJJarlC

GlOUr

(ilOUP

n1:i:utscr. 1s

(N 35)

(x • 35)

UiK

no.(%)

Physic:J compo nent
lmptO"'<'d
II (31 )
Unchan g ..-d
16 (46)
\Vor$C
8 (23)
Me nt:ll component

J,npr(l'l'<'d
Unchang1.-d
Worse

Total
lmpro-.-.:d
Unchang..-d
Wor5e

II (31)
16 (46)
8 (23)

SUtON EG ATN'E PATENTS

%

\tALUt

t9s% en

GJ.OUP

GI.OUP

na:i:nts ct 1s

I'

(x • 22)

(N• 23)

J.tiK

\'ALUt

% l9s% en

no.(%)

0.96
10 (29)
17 (49)
8 (23)

3 (-19 1024)
0 (-2010 20)

9 (41 )
9 (41 )
4 ( 18)

S (22) 19 (-710 46)
11 (48)
7 (30) - 12 ( -3710 13)

S (36)
9 (41 )
5 (23)

6 (26)
12 (52)
5 (22)

10 ( -171037)

IO (45)
6 (27)
6 (27)

7 (30)
S (35)
8 (35)

15 ( -1 3 10 43)

0.4 6
16 (4 6) - 14 (-3710 8)
12 (34)
7 (20)
3 (-16io22)
14 (40)
9 (26)
12 (34)

-3 (-26 IO 20)
0 (- 2210 22)

_.\ ~Tl8 ICITIC PLACUO
GlOUPS
GlOUPS

(x• 57)

(x• 58)

no. (o/oJ

n 1:1:u.i.x-c1t

tx

% <95%

en
0.55

20 (35)
25 (44)
12 (2 1)

15 (26) 9 (- 8 IO 26)
28 (48)
15 (26) -5 (-2010 11)

19 (33)
25 (44)
I 3 (23)

22 (38) -5 (-22wl3)
24 (41 )
12 (2 1) 2 (-131017)

23 (40)
16 (28)
18 (32)

21 (36) 4 (-14 IO 22)
17 (29)
20 (34) - 3 (- 20 lo 14)

0.7 1
I ( -231025)

0.87

0.58
- 8 (-34 lo 19 )

r
VALUll

US>.

0.34

0.96
13 (37)
10 (29)
12 (34)

All PATIENTS

AhlllJOflC rl.AC[RO

r 1..ACIIO

0.90

• Patients were considered to bl.' seropositive if they h ad a Western blm indicating su bsuntial le,·ds of scrum lgG antibodies to BorrtJia b111JJdo1ftri at
the time of enrollment in the study; p :.uieiu s were considered to be :seronegative if they h:kl a negati,•e Weste rn bl04. The antib iotic treatment regimen for
those in the anribiotic group w:1.s in1ra,-e1wus cefi riuone (2 g per d 1y) for 30 coll$eCu1i,·e d:i.~·st followed by 01•1.l dcu:ycrdine ( 200 mg per d~·) for 60
c<ms.xutin: da~·s. The d ifl~n: ncc in risk is the proportion of paticnu with impro ,"<d or ,,·ors.: scores i.n the antibio tic grou p minus the propor1ion with
impro,·<.-d or worse s,,::ores in the placebo group. P ,·a.lucs were dc1i,•1.-d by the chi•sq uarc le.st for the comparison <'A the antibiotic g roup with the placebo
group xross the thn.oe o utcome c:itegories o f "improved," " unchanged," and "worse." SF-36 d enotes Medit: ,'11 O utcomes Sn1dy 36-item Sho rt-Form Gen•
eral H e:ahh Sun-e~-, .md Cl confiden ce in1en·:al.

Note. Adapted from “Two controlled trials of antibiotic treatment in patients with persistent symptoms
and a history of Lyme disease”, by Klempner, M. S., Linden, T. H., Evans, J., Schmid, C. H., Johnson, G. M.,
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Trevino, R. P.,…Weinstein, A. W., 2001, New England Journal of Medicine, 345(2), 85-92. Copyright 2001
by the Massachusetts Medical Society.

This article by Klempner et al. (2001) also demonstrates how long the problem has
persisted. Recruitment for the study began in 1997. Standardized questionnaires were used to
determine clinical response. The problem is that results could be affected by subjective views
of the patients. Not only was extended antibiotic use addressed but adverse events were
evaluated and graded according to scales derived from the Common Toxicity Criteria of the
National Cancer Institute. Rash, diarrhea, and vaginal pruritis were more common in the
extended use antibiotic groups. No deaths occurred. The primary analysis was an intention-totreat. The study was completed by 107 patients out of 129 (83%) (Klempner et al., 2001). Any
participant completing at least 75% of the prescribed medication was still included.
In a more recent study, similar observations and conclusions were made. According to
Berende et al. (2016) a randomized, double-blind, placebo-controlled trial that included 280
participants was conducted. The 280 participants were divided into groups of 86 receiving
doxycycline, 96 receiving clarithromycin plus hydroxychloroquine, and 98 in the placebo group.
This study showed that prolonged antibiotic treatment of either doxycycline or clarithromycinhydroxycholorquine after an initial dose of ceftriaxone did not lead to a better quality of life
than the group that received the placebo. The outcomes were measured by using the RAND
SF-36 Health Status Inventory with mean scores of 35.0 across all three groups. Table 3 reflects
that the poor quality of life of these patients remained across all three groups after the
treatment. In all study groups, the SF-36 physical-component summary score increased
significantly from baseline over the study period (p=<0.001) (Berende et al., 2016). An
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incidental finding was also found to include that 68.6% of the participants experienced drugrelated adverse events.
Table 3. Treatment Effect at the End of the Treatment Period in the Modified Intention-toTreat Population
Table 2. Treatment Effect at the End oh he Treatment Period In the ModfAed lntentfon,to-Tra.l Population.•
Ooxycydine
Croup
(N•l6)

Outcome

Clarithromyd~
Hyd,oxychlotoquln• Group
(N•Mi

Placebo

Cn>up
(N•91)

PValu¥t

0.69

N'.Ort (9$%CI)

Primary outcome: Sf.] 6 physic.alcomponent summar,t
s«ond1ryoutcome1
RANOSf•ltii
Mental•t()fflpont'!'f; s\lmm.ary
Gl *l•hitllth «imposlt4

Physic.a\..funaioning sc.a&e
Aol"""phr<•I '(~ko
Bodily pl.-. so~

(jcnrral-htalth scale
Mf!ntal,hr,-;ilth ,w;;a~
Role-emotional scale
Soci1Ue,1n(tioona K4!1t:

JS.6
(34.2 to )7.1)

JO
(H.4 to )6.2)

-<0.2
(JUto, I.9)

◄0 s
()1.9 ,o,2.1)

(lUto • I.7)

J6.I
(H .S to l7.8)
4L9
(405 to43.3)
)3.6
(ll.6 tol5.6)
U.l
(37 5 to <0,7)
37,l
(lS.6tolU)
4S,1
{4l.8to 46.4J

)6,6
(l 5.l to l8.1)
42.1
(401 100.4)

~-0
(l4.S to 37.5)
41.0
(39.7 to 42.1)

34'
(l 2.S 10 16.l )

(32.0t<> ) 5.8)

..0.1

)3.9

0.94

0.◄

(•2.ltol.1)
0 ,6
(-2.1 to 3.2)
1.1
( 1110 ],4)

(-2.6 to 2.9)
0.9
( l.4 10 3,2)

08•

-OJ

39.4
CJ7,9 to <O 9)

0.42

(-l.7 to l .1)
-<l.l
(-2.9 10 2.4)

0.41

4 1.◄

(39,2 to -43.6)

(40,◄ to -4' 8)

)6.)

)8 I
(36.6 to ◄0.S)

)7.S
(lS.6tol9.S)

032
0.15

(43.9 to 46.'1)

0.1

0.44

◄-4. 7

◄S.l

◄ 2.3

4 2.◄

◄ l.9

(409to ~ .o,

(<tLO to -43,9)

(.0.S to •0 ,<t)

18.7

87.1
(8)0 1091.1)

(1'1 ,4 to 91 ◄)

386
(36.6 to ◄0. S)

(36.l to <0.2)

0.9
(-L6 tol.3)

(•2.7to 2.9)

0.1

(U .4 10 41.0,

()7,0 ,. )9.1)

0.2
(-2.◄ to 2.1)

,us

37,S
(J6,2 to 31.9)
'5,1
(43.9 to 46.4)
42.6

(34.2to)&.◄)

Vi1aJ1ty scale

◄0.S

Oaridlromyci~
Hydl'O.llychloroqulne Grot.ip
vs. Placebo Gl"Ollp

dijftrtnr.c ;,, '"'111 (95" Cl)t

35.0
(ll.5 to l6.5)

(l90 to -4l,9)
38.•

Doqit::,cline Gtoup
vs. Placebo Group

-4.•

0.5
(-2.8 to l .8)
1.1

(-1.Stol,6)
0.9

s to).))

(-2.9 to 2.0j

(-1

1.00

00
(-2.3 10 2.2)

0.11

2.1
(.-1.710 6.0,

(-2,0 to 3.1)

0,0
(- 2.l to 2.2)
-1.2
(-i O102.6)
1.0
(-2.◄ to -1.4)
0.S
(-2.0 t o l ,O)

0.)
(~6.9107.•)

( -1 l to 5.6)

l.l
(-<.7 to 2.3)

o.s
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(I◄◄ to92,9)

Fa1lcue•HVenty scale
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-1.l
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O.l

(-2.◄ to ◄ .6)

(-U to l .7)
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Note. Adapted from “Randomized trial of longer-term therapy for symptoms attributed to Lyme
disease”, by Berende, A., ter Hofstede, H. J., Vos, F. J., van Middendorp, H., Vogelaar, M. L.,
Tromp, M.,…Kullberg, B. J., 2016, The New England Journal of Medicine, 374(13), 1209-1220.
Copyright 2016 by the Massachusetts Medical Society.
Patients were appropriately randomized and blinded. Balance was established for age,
sex, and duration of symptoms. Outcomes were assessed using the RAND-36 Health Status
Inventory (RAND SF-36) which could be considered subjective. Berende et al. (2016) have again
appropriately assessed and shown that longer-term antibiotic treatment does not lead to
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better outcomes. Specific efforts were made during the study to ensure adherence to the study
regimens by using Medication Event Monitoring System caps. The authors summarized findings
from other smaller studies in comparison which had similar results. They also discussed that
several non-comparative, open-label studies have shown beneficial effects of prolonged
antimicrobial treatment, but randomized, control trials have not.
Striker (2007) does provide a counterpoint study that compares peer-reviewed
literature pertaining to diagnostic Lyme disease testing, standard treatment results, and
coinfection with other tickborne agents. The study looks at uncontrolled and controlled trials
of prolonged antibiotic therapy in patients with persistent symptoms of Lyme disease. The
author concludes that Borrelia burgdorferi can invade tissue, elude the immune system, and
establish long-term infection in patients. He states that antibiotic therapy greater than four
weeks may be beneficial for these patients.
Unfortunately, the studies cited by Striker (2007) that support better symptom
outcomes using long term antibiotics were all uncontrolled trials and published from 1994 to
1999. These uncontrolled trials do not give accurate and valid results. The controlled studies
cited had not been finished. There were not two independent reviewers of this study.
Sufficient detail or statistics were not provided. The approach suggested for treatment did not
follow current Infectious Diseases Society of America (IDSA) guidelines.
Marzec et. al (2017) discussed 5 illustrative cases that were reported to the CDC and
evaluated regarding serious bacterial infections acquired during treatment of chronic Lyme
disease. Septic shock, osteomyelitis, Clostridium difficile colitis, and paraspinal abscess being
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among the outcomes with even one patient case outcome resulting in death. This article is
limited by the small population reported and studied. The authors state that systematic
investigations would be useful to better understand the scope and consequences of adverse
effects that result from the treatment of chronic Lyme disease. These cases were identified
retrospectively after being reported to the CDC. Relevant exposures and potential confounding
factors were not addressed. Outcomes were discussed on a case to case basis.
Tseng, Cami, Goldmann, DeMaria, and Mandl (2015) performed a population-based
retrospective cohort study that analyzed claims from a nationwide US health insurance plan in
14 high prevalence states over two periods: 2004-2006 and 2010-2012. The extended use of
antibiotic definition for this study included greater than five weeks prescription. The incidence
of extended antibiotic therapy for treatment of Lyme disease was higher in 2010-2012 (14.72
per 100,000 person-years; n=684) than in 2004-2006 (9.94 per 100,000 person-years; n=394)
(p<.001) (Tseng, Cami, Goldmann, DeMaria, and Mandl, 2015).
Despite guidelines established by the Infectious Diseases Society of America (IDSA), the
study conducted by Tseng et al. (2015) shows that considerable variation remains in the length
of antibiotic use when treating Lyme disease. The study did list some factors that may have led
to overestimation such as inaccurate coding and the fact that claims data reveal tests ordered
but do not include test results. Therefore, negative test results may have been included. The
study also stated some factors that may have led to underestimation including those patients
diagnosed clinically with EM and never lab tested, therefore not meeting the post Lyme disease
definition. Also, patients treated with antibiotics in an inpatient setting would not have been
included. Some of the theories proposed about why there remains considerable variation in
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courses of therapy despite consensus on the duration by the IDSA are reasons such as belief
that longer courses of treatment are better at preventing long-term consequences, or that
persistence of Lyme disease symptoms requires more extended therapy, or some may be
related to patient fear of the possible long-term consequences of undertreated Lyme disease.
Tseng et al. (2015) states that those still treating with extended antibiotic treatments may
include a small group of providers.
Treatment of PTLDS Based on Symptoms
Myalgic encephalomyelitits/chronic fatigue syndrome.
One of the main syndromes often associated and compared to PTLDS is myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS). Both have several clinical features in
common including fatigue, musculoskeletal pain, and cognitive difficulties. Patrick et. al (2015)
conducted a case-control study enrolling 13 patients with alternatively diagnosed chronic Lyme
syndrome (ADCLS), 25 patients with chronic fatigue syndrome (CFS), 25 matched healthy
controls, and 11 patients with systemic lupus erythematosus (SLE). Patients completed a
history, physical exam, screening laboratory tests, seven functional scales, reference serology
using the Centers for Disease Control and Prevention criteria, reference serology for other tickassociated pathogens and cytokine expression studies. The baseline clinical data and functional
scales showed significant disability among both ADCLS and CFS patients when compared to the
control group but no differences between each other. Data was statistically significant at
p<0.05 as shown in Table 4. The small sample size made it harder to detect small differences
between the groups. This kind of study may suffer from recall bias as a function of strong
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personal identification with a diagnosis and its associated risk factors and symptoms. Selection
bias is also a risk but was minimized by using identical exclusion criteria across all study groups.
This study identifies ADCLS and CLS as indistinguishable based on medical histories, physical
exam functional scales and a range of laboratory tests.
Table 4. Demographic and Clinical Characteristics of the Study Cohort (N=74)
Table 2. Demographic and Clinical Characteristics of the Study Cohort (N ■ 74)
PValue
Gfoup

Male sex
Age. y. moo,an (IORI
Highest level of 80.Jc.ation
Hg h school
Undergtaduate

Postgraduate
Cutr&nt annual income, median (IQA)

Healthy (n = 25)

SLE(n= l ll

CFS Cn =25)

ADCLS (n = 131

4 (16)
53 (30-69)

0(0)
51 (29-75)

4 (16)
54 (34-67)

3 (23)
45 (18-7 1)

4 (16)
16(64)
5 (20)
$35000
($15000- $55000)

2(18)
9 (82)
0(0)
$45000
($12 500-$55000)

6(24)
13 (52)
6(24)
$35000
($17 500-S65000)

0 (0)
20(80)
.1 ( 1?)

C:hir'IAC.A

Othet
Symptom onset sudden
Core symptoms
Fatigue
Postexertiooal fatigue
Noorefreshing sloop or sloop d:sturt>ance
Pain or headache
NeufOlogical/oognitive dysfunction

Swoltoo ;oints
Painful ;oints
Mooting Fukuda CFS definition

Putative ttigg&rs associated with symptom onset
Viral illness
Bacterial infection
Tick.bite
Skin rash

2 (8)
NA
4 (16)

2 (8)
8(32)
15(60)
1 (4)
1 (4)
7 (28)
0 (0)
NA
NA
NA
NA

0(0)
5 (45)

2(8)
23 (92)

H ealthy

.7

CFS vs
ADCLS
.7

1.0
.9
.7

.9

1.0

.02

.02

7 (54)

3 (23)
$22 500
($2.500-$45000)

.7

.8

.4

.3

.08

.04

.4

.4

NA

NA

NA

.2

<.0001
<.0001
<.0001
.001
<.0001
.02
.01

<.0001

<.0001

<.0001

.3
.1
.3
1.0
.1
.3
.1
.1

NA

NA

NA

NA

.7
.7

NA
NA

NA
NA

1.0
.6

0 (0)
13 (100)

n CO)

n CO)

0 (0)
13 (52)

0 (OJ
3 (23)

9 (82)
5 (45)
8(73)
10 (91)
5 (45)
5 (45)
8(73)
0 (0)

25 (100)
25 (100)
25 (100)
25 (100)
25 (100)
8 (32)
17(68)
25 (100)

12 (92)
11 (85)
12 (92)
13 (100)
11 (85)
7 (54)
12 (92)
11 (85)

<.0001
.02
.03
.1

3(27)
1 (9)
0 (0)
5 (45)

11 (44)

7 (54)

4 (16)
4 (16)
2(8)

3 (23)
2 (15)
2 (15)

NA
NA
NA
NA

1?7)

ADCLSvs

Healthy

.3
.5
.4

3(27)
4(36)

~

CFS vs

3 (23)

Ethnicity

Aboriginal
White

SLE vs
Healthy

.006
.006
.03
1.0

<.0001

.001
.008
<.0001

.001
<.0001

Values are presented as No.(~) fOf categorical variables and median (IOR) for continuous variables. Pvalues were calculated with FtSher exact test for categorical variables or Wicoxon rank-sum test for continuous
variables.
Bold values denote statistically significant at P < .05.
Abbreviations: ADa.S, alternatively diagnosed chronic Lyme synttome; CFS, chronic fatigue syndrome; IOA, interquartie range; NA, not applicable; St£, systemic llpus erythematosu:s.

Note. Adapted from “Lyme disease diagnosed by alternative methods: A phenotype similar to
that of chronic fatigue syndrome”, by Patrick, D. M., Miller, R. R., Gardy, J. L., Parker, S. M.,
Morshed, M. G., Steiner, T. S.,…Tang, P. 2015, Clinical Infectious Diseases, 61(7), 1084-1091.
Copyright 2015 by the Oxford University Press.
In contrast, Ajamian, Cooperstock, Wormser, Vernon, & Alaedini (2015) referenced a
study done by Chandra et. al (2010) finding IgG anti-neural antibody reactivity was significantly
increased patients with PTLDS (41 of 83; 49.4%) versus patients who had been treated for Lyme
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disease and did not have residual symptoms (5 of 27; 18.5%) and healthy controls who had
never had Lyme disease (3 of 20; 15%) (p<0.01 for both comparisons). They compared this
study to their study which found no significant difference in the prevalence of anti-neural
antibody reactivity between ME/CFS patients (4 of 51; 7.8%) and healthy controls (7 of 53;
13.2%) (p=0.5) (Ajamian, Cooperstock, Wormser, Vernon, & Alaedini, 2015). As a result, antineural antibody reactivity may be a distinguishing factor between the two syndromes. This
study did list a potential limitation being the methodology of the initial study done by Chandra
et al. (2010), which primarily detects the prominent expressed neural proteins and may miss
reactivity of the minor proteins or non-protein antigens. It was suggested that further inquiry
into B cell activation mechanisms and auto antibody response may also be useful in
distinguishing between PTLDS and ME/CFS.
According to DynaMed Plus, chronic fatigue syndrome (2018) there are not FDA
approved medications for CFS. Recommended treatment options include a healthy, balanced
diet, exercise therapy (level 1 [likely reliable] evidence), counseling or behavioral therapy (level
2 [mid-level] evidence), acupuncture, and/or the recommended off-label use of
methylphenidate 10 mg twice daily for 4 weeks (level 1 evidence) but with the risk of
habituating and tolerance developing.
A cochrane review was performed by Price, Mitchell, Tidy, & Hunot (2008) where 15
studies (1043 CFS participants) were included. In 6 of the studies mean fatigue scores were
highly significant in favor of cognitive behavior therapy (CBT) compared to usual care. 40% of
the CBT participants showing clinical response compared to only 26% receiving usual care (95%
CI 0.29-0.76). In four other studies CBT was compared to other psychological therapies,
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including relaxation, counseling, and education/support. Again, the mean fatigue scores
favored CBT (95% CI -0.65 to -0.20). Limitations included inconsistent findings at follow up and
a small group of studies.
Kaiser (2015) performed an open-label, proof-of-concept trial on 15 participants that
were all given low-dose methylphenidate in combination with mitochondrial support nutrients.
At 12 weeks it was found the 87% of the participants had a greater than or equal to 25%
reduction in fatigue and concentration disturbances (p<0.0001). This study was limited in a
small study group size and did not include a placebo group for comparison.
Lyme neuroborreliosis.
Neurological symptoms are also a common finding in PTLDS. Ramesh, Martinez, Martin,
& Philipp (2017) conducted a study where dexamethasone, a steroid that inhibits the
expression of several immune mediators and meloxicam, a non-steroidal anti-inflammatory
drug that inhibits cyclooxygenase-2 (COX-2) were evaluated for effects on Borrelia burgdorferiinduced inflammation in glial and neuronal cells of the CNS. Freshly harvested frontal cortex
tissues were collected from three rhesus macaques that were euthanized in accordance with
the recommendation of the American Veterinary Medical Association’s Panel on Euthanasia.
Two-mm sections of the frontal cortexes were divided into 12-well plates. Tissue sections were
exposed to medium containing Bb spirochetes in the presence or absence of dexamethasone or
meloxicam. Controls with no spirochetes were also included. After 48 hours the tissues were
evaluated. As shown in Figure 1, dexamethasone resulted in significantly reduced levels of proinflammatory cytokines or chemokines being evaluated whereas meloxicam treatment showed
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no significant reduction in the same levels. This study tests the hypothesis that inflammatory
mediators are the key factor in Lyme neuroborreliosis (LNB). Caution is expressed for use of
steroids if facial palsy is associated with Lyme neuroborreliosis because studies have shown an
opposite effect.
Figure 1

•

b

d"

C

C

'"

"

Fig. 1 Dexamethasone but not meloxicam reduces the levels of Bb-induced cytokines and chemokines in
frontal cortex explants after 6 h of incubation. The graphs represent the effect of the anti-inflammatory
drugs on the levels of a IL-6, b IL-8, c CCL2, d IL-1β, e IL-10, f IL-18, g TNF-α, h VEGF, and i G-CSF. The
two-way ANOVA and Tukey’s multiple comparison test were used to evaluate the statistical significance
between means and SEM of triplicate data sets, *p < 0.05, **p < 0.01, ***p < 0.001

Note. Adapted from “Effects of dexamethasone and meloxicam on Borrelia burgdorferi-induced
inflammation in glial and neuronal cells of the central nervous system”, by Ramesh, G.,
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Martinez, A. N., Martin, D. S., & Philipp, M. T., 2017, Journal of Neuroinflammation, 14(1), 28.
Copyright 2017 by the Authors.
Lyme disease-associated facial palsy (LDFP) is an acute manifestation of neuroborreliosis
which is a common finding when dealing with PTLDS. A retrospective cohort study included 51
patients who had a prior diagnosis of unilateral LDFP (Jowett, Gaudin, Banks, & Hadlock, 2017).
These patients were followed to determine differences in outcomes between those that were
treated with antibiotic monotherapy (MT); dual therapy (DT) with antibiotics and
corticosteroids; and triple therapy (TT) with antibiotics, corticosteroids, and antivirals. These
patients were followed for up to 84 months. Significantly worse facial outcomes were seen in
patients receiving DT and TT compared to MT. This study demonstrates an association between
corticosteroid use in acute LDFP and worse long-term facial function. Care still needs to be
taken in initial diagnosis to distinguish between viral, idiopathic facial palsy or LDFP. Bias was
found in that the sample population was principally representative of a smaller subset of LDFP
patients who develop post paralysis facial palsy. Bias was also found in patient self-selection to
the testing center. Confounding factors included the proportion of patients prescribed
antibiotics alone versus with corticosteroids in the general population because it is currently
unknown.
Lyme arthritis.
More than a third of the Lyme disease cases reported to the CDC involve arthritis as the
manifestation of the presenting disease (Arvikar & Steere, 2015). The location is usually one or
a few of the larger joints presenting with pain and swelling. Diagnosis is usually made by PCR
testing of the synovial fluid positive for Bb before treatment. It however is not a reliable
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marker for eradication of Bb after treatment. Arvikar & Steere (2015) discussed treatment
recommended by the IDSA that used several small, double blinded or randomized studies to
determine an algorithm presented below in Figure 2. Initial use of oral doxycycline with
minimal or no improvement of symptoms has seen moderate improvement when treatment is
switched to IV administration. Arvikar & Steere (2015) recommends combination therapy using
NSAIDS (ibuprofen or naproxen) and DMARDs (hydroxychloroquine or methotrexate) to treat
persistent arthritis after initial treatment. The last resort may be a synovectomy.
Figure 2

Diagnosis of Lyme arthritis
•Patient with mono or oligoarticular arthritis, especially involving the knee

•Exposure to endemic area, but may not recall EM or tick bite
•Positive antibody response to 8 burgdo,feri by ELISA and lgG Western blot
•Optional: positive PCR test in synovial fluid

•

Initial treatment
•Oral doxycycline or amoxicillin for 30 days, as per IOSA guidelines"
•Use IV regimen if concurrent neurologic involvement

Complete response

Mild persistent arthritis

Moderate/severe persistent arthritis

•No further antibiotic treatment

•Treat with additional 30 days of
doxycycline

• IV ceftriaxone for 30 days,
as per IDSA guidelines36

• Start physical therapy

r

Persistent arth ritis after ant ibiotics
•If arthritis is mild, treat with NSAIO or hydroxychloroquine
•If arthritis is moderate to severe, treat with methotrexate
•If arthritis persists for 3·6 months despite OMARDS, consider synovect omy

Fig. 2. Algorithm for the diagnosis and ueatment of Lyme arthdtis. DMAROS. disease modifying antifheumatic dfug:s; ELISA, en2:yme--llnked immuno•
sorbent assay; EM. efY1-he-ma migfans; IOSA. lnfe<tious Disease Society o·f America; IV, intravenous: NSAID. nonstefoidal a.ntiinfl.ammatory drug; PCR.
polymerase thain feaction.

Note. Adapted from “Diagnosis and treatment of Lyme disease”, by Arvikar, S. L. & Steere,
A. C., Infectious Disease Clinics of North America, 29(2), 269-280. Copyright 2015 by the Elsevier
Inc.
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Alternative Treatment Options for PTLDS
Lantos et al. (2015) performed internet searches using Google to identify what websites
were marketing nonantimicrobial therapies for Lyme disease. Then PubMed was used to
identify any scientific evidence to support these treatments. The authors categorized more
than 30 alternative treatments found through the internet search into five broad categories.
The categories included oxygen therapy, energy and radiation treatments, metal chelation,
nutritional supplements, and biological/pharmacologic therapies. Review of the medical
literature did not substantiate any efficacy for the advertised treatments found on the internet
through Google.
Lantos et al. (2015) references the study done by Klempner et al. (2001) with 38% of
placebo-treated patients having improved symptoms. This proportion was not significantly
different than the patients who received antibiotics. The authors also found that the studies
showing extended antimicrobial therapy ineffective with convincing evidence of possible harm
justifies the website’s promotion of alternative therapies is the only other option. This study
admits to not presenting a comprehensive catalogue of the unorthodox therapies offered as
this list continues to change. The study cannot measure how popular these nonconventional
therapies are among patients.
Essential oils.
Feng et al. (2017) performed a study where 34 different essential oils were evaluated.
Aliquots of these oils were added to a 96-well plate containing 110 uL of the seven-day-old
stationary phase Borrelia burgdorferi culture. Each essential oil was assayed in four
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concentration levels. An antibiotic combination of daptomycin, doxycycline, and cefuroxime
was used as the control drug since it had been shown to completely eradicate Bb persisters in
previous studies. A drug-free control was also included. All tests were run in triplicate. Results
were obtained after 7 days of incubation. Oregano and cinnamon bark showed remarkable
activity even at 0.05% concentration for complete eradication of the stationary phase of Bb. It
was also noted that oregano oil dramatically reduced the size of aggregated biofim-like
microcolonies compared to the antibiotic controls.
Though the Feng et al. (2017) study shows promise for alternative treatment options for
Lyme disease, they caution that many factors still need to be considered. Future studies need
to identify the active ingredients in the specific oils and determine effective dosage in vivo.
Though carvacrol, the active ingredient in oregano, has not shown toxicity in mice, there is
limited safety information regarding essential oil use in humans. Adequate animal studies need
to confirm safety and efficacy of active essential oils before human studies can proceed. This
study also indicates that further studies are needed to find an antimicrobial agent that
penetrates the blood-brain barrier as well as the persistent Borrelia organisms do.
Supplements.
Nicolson, Settineri, & Ellithorpe (2012) conducted an open label study to determine if
using a combination oral supplement containing a mixture of phosphoglycolipids, Coenzyme
Q10, and microencapsulated NADH (marketed as ATP Fuel) could affect fatigue levels.
Participants included 58 patients with chronic fatigue syndrome/myalgic encephalomyelitis,
chronic Lyme disease, or other fatiguing illnesses. These patients took the recommended daily
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dose for 8 weeks. The level of fatigue was measured by using the validated Piper Fatigue Scale.
The study showed a 30.7% reduction in overall fatigue within 60 days (p<0.001) (Nicolson,
Settineri, & Ellithorpe, 2012). The combination supplement was found to be both safe and
effective.
An open label study is not as reliable and unbiased as a randomized control study.
There is not a placebo group so there is a chance that these patients could have felt better after
eight weeks even without treatment. According to Nicolson, Settineri, & Ellithorpe (2012)
statistical analysis was performed using ANOVA and Turkey test and linear regression analysis,
with significance defined as p<0.05. The regression analysis suggests that the data was
consistent with a high degree of confidence, but the trial may have ended too soon and the
peak benefits on fatigue were yet to be realized. Only two participants experienced minor
symptoms, but this could not be directly linked to the supplement since their problems
preceded entry into the trial.
DISCUSSION
Chronic Lyme disease and post treatment Lyme disease syndrome are still being used
interchangeably. No matter what the problem is called, the fact that Feng et al. (2017) states
that 10-20% of patients diagnosed and treated for Lyme disease continue to be symptomatic is
too much to be ignored. A case definition has been established by the IDSA. Rebman et al.
(2017) found that 59% of the participants with PTLDS were either misdiagnosed or diagnosis
was delayed. This stresses the importance of keeping Lyme disease in the differential diagnosis
for typical symptoms occurring in endemic areas or those who have travelled to endemic areas.
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This subset of patients with PTLDS present with a spectrum of symptoms that have a big impact
on the quality of life. Patient’s jobs, schooling, and personal relationships are negatively
affected. Those providers practicing in these endemic areas need to know how to
appropriately manage and treat these patients.
Further research needs to be done to develop more specific and sensitive lab tests so
that concrete diagnoses can be made when clinical symptoms are not as straight forward as
EM. Rebman, Crowder, Kirkpatrick, & Aucott (2015) established that Lyme seroreactivity
should not be retested after the initial positive test because it does not correlate with ongoing
symptoms. It would also be beneficial if the lab test could be used to identify if PTLDS is truly
caused by residual Lyme disease or other inflammatory/infectious conditions. Studies that
describe precisely the risk factors and mechanisms of illness to guide improvement of
diagnostic specifics and treatment options would be beneficial.
One of the questions that remains and needs to be researched further is if these
symptoms are a direct or indirect consequence of Lyme disease. The study by Middelveen et al.
(2018) does indicate the possibility of Borrelia spirochetes surviving initial treatment, but with a
study group of only 12 patients and other problems stated with the study, further research is
needed. This study does however provide evidence that persistent infection is at least partly
responsible for ongoing symptoms in Lyme disease. If this question is answered, we may be
able to establish guidelines for treatment. As of now the literature is showing that we have no
concrete answers.
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In patients who were treated appropriately for Lyme disease but develop PTLDS, does
extended course antibiotic therapy versus symptomatic treatment versus alternative
treatments help relieve PTLDS symptoms most effectively?
Family practice providers must be aware of Lyme disease symptoms and appropriately
treat these patients to the best of our abilities as soon as possible to try to prevent PTLDS. As
for treatment of PTLDS, the one area of study that shows the most research is the use of
extended antibiotics. These studies show that extended use of antibiotics in treatment of
PTLDS is not beneficial and increases the risk of adverse effects. The study done by Klempner et
al. (2001) proving this, still holds true after all these years and was again justified by another
large study done by Berende et al. (2016). Numerous smaller studies have been done in
between. All studies showing that there are no significant differences in outcomes between
those patients treated with long term antibiotics versus the placebo groups. Striker (2007) was
unable to support the counterpoint of benefit of long-term antibiotics in his article only using
uncontrolled studies without accurate or valid results. What Striker (2007) does provide is
evidence that the theory of extended use of antibiotic treatment for chronic Lyme disease was
challenged and not just assumed. Marzec et al. (2017) established that even though the risk of
adverse reactions to extended use of antibiotics is small, it is still a factor that needs to be
considered. The adverse effects of these cases represent the need for patients and health care
providers to be informed of the risk of inappropriate antibiotic use.
What is interesting is that even though the studies prove that extended antibiotic use is
not effective in treating PTLDS and the risk of adverse reactions remains, it is still being done.
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As established by Tseng, Cami, Goldmann, DeMaria, and Mandl (2015), the fact that extended
antibiotic use is still being prescribed is most likely a consequence of not having established
guidelines for treatment of PTLDS. Providers are at a loss of what to do for their patients that
are suffering from persistence of symptoms.
In contrast to the concrete evidence showing that extended use of antibiotics is not
beneficial, there have been potential studies showing that alternative therapies may be
something of use in the future. With studies being done by Feng et al. (2017) on animals using
oregano or cinnamon bark to eradicate the borrelia spirochetes, human studies for dosing and
safety concerns still need to be done. Nicolson, Settineri, & Ellithorpe (2012) have established
that supplements can safely help improve the fatigue portion of the symptoms of PTLDS but
does not address the other symptoms associated with PTLDS.
One of the controversies that remains over PTLDS is that without concrete diagnostic
measures there is overlap when just diagnosing using symptoms. That leaves the only option
for treating patients with PTLDS as assessing every individual patient separately and treating
the symptoms appropriately. The fatigue, musculoskeletal pain, and cognitive difficulties of
PTLDS are clinically similar to ME/CFS as established by Patrick et al. (2015) and one may want
to try treatment options that have been studied and used for ME/CFS such as diet, exercise,
counseling or behavioral therapy, acupuncture, and/or recommended off-label use of
methylphenidate (DynaMed Plus, chronic fatigue syndrome, 2018).
With Lyme neuroborreliosis, Ramesh, Martinez, Martin, & Philipp (2017) established
that the use of dexamethasone was more effective than meloxicam for treatment of all
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neurological symptoms except for facial palsy. The exception to this rule was presented by
Jowett, Gaudin, Banks, & Hadlock (2017) establishing that corticosteroids and antivirals lead to
worse long-term facial function compared to the monotherapy of antibiotics which is the
recommended treatment for LDFP. Implications of dexamethasone regarding the treatment of
human disease still are not clear. Further evaluation is required to ascertain which inhibitors of
inflammation may be safely used to mitigate signs and symptoms of LNB.
Arvikar & Steere (2015) lists a treatment algorithm established by the IDSA as the
guideline for treating Lyme arthritis which is similar to chronic inflammatory arthritis by using
NSAIDS and DMARDS if antibiotics are unsuccessful. Synovectomy would be the last resort.
It is not surprising that with the controversy regarding chronic Lyme disease, patients
would seek answers from the internet. The easy accessibility to testimonials from patients in
the form of online blogs, discussion boards, and promotional materials by alternative therapy
can be persuasive to vulnerable populations of patients suffering prolonged symptoms. Calling
attention to these unconventional treatment options may serve to discourage their use. It is
important for healthcare providers treating these patients that attribute their symptoms to
chronic Lyme disease, to provide counseling and education about the risks and costs of
unconventional therapies.
APPLICATION TO CLINICAL PRACTICE
Even though the controversy continues, PTLDS does have a case definition and studies
showing that symptoms can persist after appropriate treatment of Lyme disease. If the patient
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falls under the case definition, symptoms should be taken seriously and treated appropriately
so that these patient’s quality of life is improved to the best of our abilities.
What is known and proven by numerous studies shows that extended use of antibiotic
therapy is not appropriate or beneficial in most cases of PTLDS. The studies also show that
patients are at increased risk of adverse effects with use of extended antibiotic treatment. The
exception to this rule appears to be with Lyme arthritis which recommends an additional 30day treatment with doxycycline or ceftriaxone if still symptomatic.
The use of alternative treatment options has not been studied thoroughly enough on
the human population to be safely recommended by the medical community. Patients must be
warned that the efficacy of treatments listed on the internet, such as oxygen therapy, energy
and radiation treatments, metal chelation, nutritional supplements/essential oils, and
biological/pharmacologic therapies, are not evidence based and therefore, should be avoided.
Again, there is one exception, as the supplement ATP Fuel has been proven to help decrease
the symptom of fatigue.
Therefore, the most appropriate treatment option left for providers to follow is to treat
each patient individually according to their specific symptoms. Fatigue, musculoskeletal pain,
and cognitive difficulties, with similarities to ME/CFS, may include treatment such as diet,
exercise, cognitive behavioral therapy, acupuncture, or off-label methylphenidate. The best
treatment outcomes for Lyme neuroborreliosis seem to be with dexamethasone, except in the
case of facial palsy where monotherapy of antibiotics is recommended. Lyme arthritis, if not
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